Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

• Status: Recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital

Criteria

Inclusion Criteria:

• Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification

• Treatment naive

• Age ≥ 18 years

• Indications for treatment confirmed

• Must has measurable lesion in CT or PET-CT prior to treatment

• Considered suitable for RCHOP, BR or R2 regimens

• Informed consented

Exclusion Criteria:

• Transformed follicular lymphoma or 3B follicular lymphoma;

• HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive

• Central nervous system or meninges involved

• Any drug contraindication in the treatment plan

• Patients judged by other researchers to be unsuitable for inclusion in the study